A Case of HLA-DRB1-MET Rearranged Lung Adenocarcinoma With Rapid Response to Crizotinib

被引：8
作者：
Kunte, Siddharth [1 ]
Stevenson, James [1 ]
机构：
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
来源：
CLINICAL LUNG CANCER | 2021年 / 22卷 / 03期
关键词：
Crizotinib; HLA-DRB1-MET rearrangement; MET fusions; Non-small-cell lung cancer; Targeted treatments; CANCER;
D O I：
10.1016/j.cllc.2020.05.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MET gene rearrangements are rare but actionable alterations found in lung adenocarcinomas. Next-generation sequencing can help identify MET rearrangements. Crizotinib has shown excellent responses for MET rearranged lung adenocarcinomas in case reports. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码：E298 / E300
页数：3
相关论文
共 17 条
  • [1] KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma
    Cho, Jang Ho
    Ku, Bo Mi
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (03) : E29 - E31
  • [2] Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion
    Davies, Kurtis D.
    Ng, Terry L.
    Estrada-Bernal, Adriana
    Le, Anh T.
    Ennever, Peter R.
    Camidge, D. Ross
    Doebele, Robert C.
    Aisner, Dara L.
    [J]. JCO PRECISION ONCOLOGY, 2017, 1 : 1 - 6
  • [3] Ettinger DS., NCCN Guidelines Version 1.2022 Non-Small Cell Lung Cancer Continue NCCN Guidelines Panel Disclosures
  • [4] Tepotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14-skipping mutations: Phase II trial.
    Felip, Enriqueta
    Horn, Leora
    Patel, Jyoti D.
    Sakai, Hiroshi
    Scheele, Juergen
    Bruns, Rolf
    Paik, Paul K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
    Jordan, Emmet J.
    Kim, Hyunjae R.
    Arcila, Maria E.
    Barron, David
    Chakravarty, Debyani
    Gao, JianJiong
    Chang, Matthew T.
    Ni, Andy
    Kundra, Ritika
    Jonsson, Philip
    Jayakumaran, Gowtham
    Gao, Sizhi Paul
    Johnsen, Hannah C.
    Hanrahan, Aphrothiti J.
    Zehir, Ahmet
    Rekhtman, Natasha
    Ginsberg, Michelle S.
    Li, Bob T.
    Yu, Helena A.
    Paik, Paul K.
    Drilon, Alexander
    Hellmann, Matthew D.
    Reales, Dalicia N.
    Benayed, Ryma
    Rusch, Valerie W.
    Kris, Mark G.
    Chaft, Jamie E.
    Baselga, Jose
    Taylor, Barry S.
    Schultz, Nikolaus
    Rudin, Charles M.
    Hyman, David M.
    Berger, Michael F.
    Solit, David B.
    Ladanyi, Marc
    Riely, Gregory J.
    [J]. CANCER DISCOVERY, 2017, 7 (06) : 596 - 609
  • [6] A Novel CAV1-MET Fusion in SCLC Transformation Responds to Crizotinib and Osimertinib Treatment
    Liu, Jun
    Li, Xin
    Peng, Jun
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : E126 - E128
  • [7] Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib
    Nelson, Annie W.
    Schrock, Alexa B.
    Pavlick, Dean C.
    Ali, Siraj M.
    Atkinson, Emily C.
    Chachoua, Abraham
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (02) : E27 - E29
  • [8] Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
    Paik, Paul K.
    Drilon, Alexander
    Fan, Pang-Dian
    Yu, Helena
    Rekhtman, Natasha
    Ginsberg, Michelle S.
    Borsu, Laetitia
    Schultz, Nikolaus
    Berger, Michael F.
    Rudin, Charles M.
    Ladanyi, Marc
    [J]. CANCER DISCOVERY, 2015, 5 (08) : 842 - 849
  • [9] Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population
    Pan, Yunjian
    Zhang, Yang
    Ye, Ting
    Zhao, Yue
    Gao, Zhendong
    Yuan, Hui
    Zheng, Difan
    Zheng, Shanbo
    Li, Hang
    Li, Yuan
    Jin, Yan
    Sun, Yihua
    Chen, Haiquan
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : 2003 - 2008
  • [10] Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients
    Plenker, Dennis
    Bertrand, Miriam
    de Langen, Adrianus J.
    Riedel, Richard
    Lorenz, Carina
    Scheel, Andreas H.
    Mueller, Judith
    Braegelmann, Johannes
    Dassler-Plenker, Juliane
    Kobe, Carsten
    Persigehl, Thorsten
    Kluge, Alexander
    Wurdinger, Thomas
    Schellen, Pepijn
    Hartmann, Gunther
    Zacherle, Tobias
    Menon, Roopika
    Thunnissen, Erik
    Buettner, Reinhard
    Griesinger, Frank
    Wolf, Juergen
    Heukamp, Lukas
    Sos, Martin L.
    Heuckmann, Johannes M.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (06) : 1337 - 1343
12